Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease

Vicente Torres, Xiaofang Wang, Qi Qian, Stefan Somlo, Peter C Harris, Vincent H. Gattone

Research output: Contribution to journalArticle

314 Citations (Scopus)

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease. The vasopressin V2 receptor (VPV2R) antagonist OPC31260 has been effective in two animal models of PKD with pathologies that are probably related. Here we show, in a mouse model of ADPKD (Pkd2 -/tms1m), a similar cellular phenotype and response to OPC31260 treatment, with reduction of renal cyclic AMP (cAMP) levels, prevention of renal enlargement, marked inhibition of cystogenesis and protection of renal function.

Original languageEnglish (US)
Pages (from-to)363-364
Number of pages2
JournalNature Medicine
Volume10
Issue number4
DOIs
StatePublished - Apr 2004

Fingerprint

Autosomal Dominant Polycystic Kidney
Kidney
Vasopressin Receptors
Pathology
Cyclic AMP
Chronic Kidney Failure
Animals
Animal Models
Phenotype

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. / Torres, Vicente; Wang, Xiaofang; Qian, Qi; Somlo, Stefan; Harris, Peter C; Gattone, Vincent H.

In: Nature Medicine, Vol. 10, No. 4, 04.2004, p. 363-364.

Research output: Contribution to journalArticle

Torres, Vicente ; Wang, Xiaofang ; Qian, Qi ; Somlo, Stefan ; Harris, Peter C ; Gattone, Vincent H. / Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. In: Nature Medicine. 2004 ; Vol. 10, No. 4. pp. 363-364.
@article{6f42830c045044e0b25f0b40a3a32d7e,
title = "Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease",
abstract = "Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease. The vasopressin V2 receptor (VPV2R) antagonist OPC31260 has been effective in two animal models of PKD with pathologies that are probably related. Here we show, in a mouse model of ADPKD (Pkd2 -/tms1m), a similar cellular phenotype and response to OPC31260 treatment, with reduction of renal cyclic AMP (cAMP) levels, prevention of renal enlargement, marked inhibition of cystogenesis and protection of renal function.",
author = "Vicente Torres and Xiaofang Wang and Qi Qian and Stefan Somlo and Harris, {Peter C} and Gattone, {Vincent H.}",
year = "2004",
month = "4",
doi = "10.1038/nm1004",
language = "English (US)",
volume = "10",
pages = "363--364",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease

AU - Torres, Vicente

AU - Wang, Xiaofang

AU - Qian, Qi

AU - Somlo, Stefan

AU - Harris, Peter C

AU - Gattone, Vincent H.

PY - 2004/4

Y1 - 2004/4

N2 - Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease. The vasopressin V2 receptor (VPV2R) antagonist OPC31260 has been effective in two animal models of PKD with pathologies that are probably related. Here we show, in a mouse model of ADPKD (Pkd2 -/tms1m), a similar cellular phenotype and response to OPC31260 treatment, with reduction of renal cyclic AMP (cAMP) levels, prevention of renal enlargement, marked inhibition of cystogenesis and protection of renal function.

AB - Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease. The vasopressin V2 receptor (VPV2R) antagonist OPC31260 has been effective in two animal models of PKD with pathologies that are probably related. Here we show, in a mouse model of ADPKD (Pkd2 -/tms1m), a similar cellular phenotype and response to OPC31260 treatment, with reduction of renal cyclic AMP (cAMP) levels, prevention of renal enlargement, marked inhibition of cystogenesis and protection of renal function.

UR - http://www.scopus.com/inward/record.url?scp=1942486801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942486801&partnerID=8YFLogxK

U2 - 10.1038/nm1004

DO - 10.1038/nm1004

M3 - Article

VL - 10

SP - 363

EP - 364

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 4

ER -